CD274 and non-small cell lung carcinoma: The results of KEYNOTE-042 30 which recruited treatment-naïve stage IIIB-IV NSCLC patients with a PD-L1 tumor-expression level ≥1% demonstrated patients in the pembrolizumab group enduring a prolonged OS compared with chemotherapy group.